Business
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancersPhase 2 study met all primary efficacy endpoints a
About this update from Sanofi Sa
[{"type":"image","alt":"Sanofi Winthrop Industrie","displaySize":"","headline":null,"caption":"Sanofi Winthrop Industrie","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/njIuMc8eT.GfUOY8hGPCUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137","width":300,"height":84}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":10000,"height":2211,"url":"https://media.zenfs.com/en/globenewswire.com/574a9ade3e77f2dc981da11efa287319"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/R8oXweyWA32SvRSO4Idb5w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIxMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/574a9ade3e77f2dc981da11efa287319","width":960,"height":212},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lCe6cBiULdwARk9mzGoghg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/574a9ade3e77f2dc981da11efa287319","width":1200,"height":265}}},{"type":"text","content":"","length":12,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":355,"height":213,"url":"https://media.zenfs.com/en/globenewswire.com/43e5e291e56c420df3d3b945857d826d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/E3HuHkQRQAWayW8Q25xcVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/43e5e291e56c420df3d3b945857d826d","width":355,"height":213}}},{"type":"text","content":"ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors","length":142,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficu...